From $375,000 to just $39.50: Budget lifeline for children suffering spinal muscular atrophy - (The Sydney Morning Herald via NewsPoints Desk)

  • As of June, the spinal muscular atrophy drug Spinraza will be listed on Australia's Pharmaceutical Benefits Scheme for $39.50 per script, and $6.40 for concessional patients, reported The Sydney Morning Herald.

  • "Those families who currently have children that are dealing with this condition have to shell out almost $375 000 a year," noted Treasurer Scott Morrison.

  • He added that "those families are already going to be able to access their drugs right now, we have been working with the medicine sector to ensure they can achieve it right now. That will reduce that to less than $40 a script. That's a cost of $240 million."

  • The independent Pharmaceutical Benefits Advisory Committee recommended the listing in April after having rejected it in 2017.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.